GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Reports Q2 FY27 Standalone Profit After Tax of Rs. 861.92 Million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 27 Oct 2026, 10:06 AM IST  ·  BSE ID: ad832c9e-5573-45fc-9a5c-3ed736b3ac57
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results, showing revenue of Rs. 5,144.96 Million and a profit of Rs. 861.92 Million for the recent quarter.
🤖 AI Summary
  • Standalone revenue from operations was Rs. 5,144.96 Million for the quarter ended September 30, 2026.
  • Profit after tax stood at Rs. 861.92 Million for the quarter ended September 30, 2026.
  • Half-year revenue from operations was Rs. 9,609.67 Million for the period ended September 30, 2026.
  • Half-year profit after tax reached Rs. 1,374.17 Million for the six months ended September 30, 2026.
  • Basic earnings per share for the quarter was Rs. 7.52.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Quarter)
5,144.96 Million
37.13
Standalone Profit after tax (Quarter)
861.92 Million
132.32
Standalone Revenue from operations (Half Year)
9,609.67 Million
38.03
Standalone Profit after tax (Half Year)
1,374.17 Million
121.94
Basic Earnings per share (Quarter)
7.52
132.10
🏢 How This Affects the Company
📈
Business Impact
The company's standalone revenue from operations increased, indicating growth in its core business activities during the quarter and half-year periods.
💰
Financial Impact
Profitability improved for both the quarter and six months ended September 30, 2026, contributing to an increase in total equity to Rs. 60,879.97 Million.
⚙️
Operational Impact
Consumables expense significantly increased to Rs. 1,414.94 Million for the half-year, up from Rs. 925.26 Million in the prior comparable period, suggesting higher input usage.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders will observe the company's financial performance through increased standalone revenue from operations and profit after tax for the quarter and half year ended September 30, 2026.
🔍
Management Signal
The financial results indicate management's focus on operational growth and improving profitability, as evidenced by the increased revenue and profit figures.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess sustained revenue and profit growth.
Capital expenditure details — review changes in Property, plant and equipment.
Borrowing levels — monitor changes in non-current and current borrowings.
MEDIUM RISK Significant increase in non-current borrowings requires monitoring despite improved profitability.
💡 Investor Takeaway
Onesource Specialty Pharma reported standalone revenue from operations of Rs. 5,144.96 Million for Q2 FY27, up from Rs. 3,751.87 Million in Q2 FY26. Profit after tax for the quarter increased to Rs. 861.92 Million from Rs. 371.01 Million. Half-year profit reached Rs. 1,374.17 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit after tax for the quarter ended September 30, 2026, increased to Rs. 861.92 Million from Rs. 371.01 Million in the corresponding prior quarter.
  • Revenue from operations grew to Rs. 5,144.96 Million in Q2 FY27 from Rs. 3,751.87 Million in Q2 FY26.

⚠️ Concerns

  • Non-current borrowings increased to Rs. 5,842.25 Million as of September 30, 2026, from Rs. 1,960.19 Million as of March 31, 2026.
  • Cash and cash equivalents decreased to Rs. 86.25 Million as of September 30, 2026, from Rs. 280.59 Million as of March 31, 2026.
📅 Company Track Record
In Q4 FY26, Onesource Specialty Pharma reported revenue up 47% QoQ to ₹4,282 million, with EBITDA expanding over 5x to ₹919 million, indicating a trend of strong performance leading into FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Onesource Specialty Pharma's standalone revenue from operations for the quarter ended September 30, 2026?
Onesource Specialty Pharma's standalone revenue from operations was Rs. 5,144.96 Million for the quarter ended September 30, 2026.
What was the standalone profit after tax for Onesource Specialty Pharma in the quarter ended September 30, 2026?
The standalone profit after tax for Onesource Specialty Pharma was Rs. 861.92 Million for the quarter ended September 30, 2026.
How did Onesource Specialty Pharma's half-year revenue perform for the period ended September 30, 2026?
Onesource Specialty Pharma's standalone revenue from operations for the six months ended September 30, 2026, was Rs. 9,609.67 Million.
What were the standalone basic earnings per share for Onesource Specialty Pharma for the quarter ended September 30, 2026?
The standalone basic earnings per share for Onesource Specialty Pharma was Rs. 7.52 for the quarter ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.